Literature DB >> 19671346

[Guidelines for percutaneous coronary intervention (2009)].

.   

Abstract

Mesh：

Year:  2009        PMID： 19671346

Source DB:  PubMed          Journal:  Zhonghua Xin Xue Guan Bing Za Zhi        ISSN： 0253-3758


× No keyword cloud information.
  6 in total

1.  Development of local clinical practice guidelines in the real world: an evolving scene in China.

Authors:  Joey Sw Kwong; Xin Sun
Journal:  Heart Asia       Date:  2017-06-16

2.  Effect of enoxaparin on clinical events after percutaneous coronary intervention.

Authors:  Nianzhong Tang; Shaoping Chen; Xiuying Shi; Zhong Ye; Xing Zheng
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention.

Authors:  Guo-Hua Zheng; Jian-Ping Liu; Nissi S Wang; Hai-Ying Chen; Jian-Feng Chu
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-16       Impact factor: 2.629

4.  Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) retrospective study of coronary catheterisation and percutaneous coronary intervention.

Authors:  Jing Li; Kumar Dharmarajan; Xi Li; Zhenqiu Lin; Sharon-Lise T Normand; Harlan M Krumholz; Lixin Jiang
Journal:  BMJ Open       Date:  2014-03-07       Impact factor: 2.692

5.  Treatment of Danhong Injection Combined with Naoxintong Capsule in Acute Coronary Syndrome Patients Undergoing PCI Operation: Study for a Randomized Controlled and Double-Blind Trial.

Authors:  Shuai Zhao; Yong Tang; Hairong Cai; Weifeng Liu; Lieyuan Zhang; Dongjie Chen; Bojun Chen
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-07       Impact factor: 2.629

6.  Clinical analysis of lectin-like oxidized low-density lipoprotein receptor-1 in patients with in-stent restenosis after percutaneous coronary intervention.

Authors:  Junfeng Liu; Yunde Liu; Kegang Jia; Zhixiao Huo; Qianyu Huo; Zhili Liu; Yongshu Li; Xuejing Han; Rong Wang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.